Andrew T Gustin1, Andrea R Thurman2, Neelima Chandra2, Luca Schifanella3, Maria Alcaide4, Raina Fichorova5, Gustavo F Doncel2, Michael Gale6, Nichole R Klatt7. 1. Department of Global Health, University of Washington, Seattle, WA; Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN; Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA. 2. CONRAD, Eastern Virginia Medical School, Norfolk, VA. 3. Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN. 4. Department of Medicine. 5. Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA. 6. Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA. 7. Division of Surgical Outcomes and Precision Medicine Research, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN; Department of Pediatrics, University of Miami, Miami, FL. Electronic address: klat0037@umn.edu.
Abstract
BACKGROUND: Bacterial vaginosis-a condition defined by a shift from Lactobacillus dominance to a polymicrobial, anaerobic bacterial community-increases the risk of acquiring sexually transmitted infections and other complications of the female reproductive tract. Antibiotic treatment frequently fails to return the microbiome to an optimal Lactobacillus-dominated state. No criteria currently exist to identify the patients likely to experience treatment failure. OBJECTIVE: We sought to identify the pretreatment community signatures associated with treatment failure through 16S ribosomal RNA gene analysis. STUDY DESIGN: Twenty-eight women who were enrolled in an oral metronidazole treatment trial of bacterial vaginosis were studied. Cervicovaginal lavage samples were collected before metronidazole treatment and at 7 and 30 days posttreatment. Cervicovaginal lavage DNA was amplified and sequenced using a paired-end, V4 region 2×150 MiSeq run. RESULTS: Of the 28 women, 25% failed to clear bacterial vaginosis; 35.7% demonstrated a transient clearance, shifting to community-type 2 (Lactobacillus iners dominant) at visit 2 only; 7.1% demonstrated a delayed clearance, reaching community-type 2 at the final visit only; and 32.1% of patients experienced sustained bacterial vaginosis clearance. Examination of the community composition and structure demonstrated that both the richness and the evenness were significantly lower for the women who experienced sustained clearance, whereas the women who failed to clear bacterial vaginosis possessed the highest median levels of richness, evenness, and diversity pretreatment. Soluble immune factors in the lower reproductive tract improved significantly following a shift from community-type 4 to a Lactobacillus-dominant microbiome, with the samples categorized as community-type 2 possessing significantly higher levels of secretory leukocyte protease inhibitor, growth-regulated alpha protein, and macrophage inflammatory protein-3 and significantly lower levels of intercellular adhesion molecule-1. Although the shifts to Lactobacillus dominance improved the markers of mucosal tissue health, these gains were only temporary among the women who experienced recurrence. CONCLUSION: Assemblies of highly diverse microbiota are associated with the enhanced resilience of bacterial vaginosis to standard metronidazole treatment. These communities may be foundational to treatment resistance or simply an indication of a well-established community made possible by canonical biofilm-forming taxa. Future studies must target the transcriptional activity of these communities under the pressure of antibiotic treatment to resolve the mechanisms of their resistance.
BACKGROUND: Bacterial vaginosis-a condition defined by a shift from Lactobacillus dominance to a polymicrobial, anaerobic bacterial community-increases the risk of acquiring sexually transmitted infections and other complications of the female reproductive tract. Antibiotic treatment frequently fails to return the microbiome to an optimal Lactobacillus-dominated state. No criteria currently exist to identify the patients likely to experience treatment failure. OBJECTIVE: We sought to identify the pretreatment community signatures associated with treatment failure through 16S ribosomal RNA gene analysis. STUDY DESIGN: Twenty-eight women who were enrolled in an oral metronidazole treatment trial of bacterial vaginosis were studied. Cervicovaginal lavage samples were collected before metronidazole treatment and at 7 and 30 days posttreatment. Cervicovaginal lavage DNA was amplified and sequenced using a paired-end, V4 region 2×150 MiSeq run. RESULTS: Of the 28 women, 25% failed to clear bacterial vaginosis; 35.7% demonstrated a transient clearance, shifting to community-type 2 (Lactobacillus iners dominant) at visit 2 only; 7.1% demonstrated a delayed clearance, reaching community-type 2 at the final visit only; and 32.1% of patients experienced sustained bacterial vaginosis clearance. Examination of the community composition and structure demonstrated that both the richness and the evenness were significantly lower for the women who experienced sustained clearance, whereas the women who failed to clear bacterial vaginosis possessed the highest median levels of richness, evenness, and diversity pretreatment. Soluble immune factors in the lower reproductive tract improved significantly following a shift from community-type 4 to a Lactobacillus-dominant microbiome, with the samples categorized as community-type 2 possessing significantly higher levels of secretory leukocyte protease inhibitor, growth-regulated alpha protein, and macrophage inflammatory protein-3 and significantly lower levels of intercellular adhesion molecule-1. Although the shifts to Lactobacillus dominance improved the markers of mucosal tissue health, these gains were only temporary among the women who experienced recurrence. CONCLUSION: Assemblies of highly diverse microbiota are associated with the enhanced resilience of bacterial vaginosis to standard metronidazole treatment. These communities may be foundational to treatment resistance or simply an indication of a well-established community made possible by canonical biofilm-forming taxa. Future studies must target the transcriptional activity of these communities under the pressure of antibiotic treatment to resolve the mechanisms of their resistance.
Authors: Thomas L Cherpes; Harold C Wiesenfeld; Melissa A Melan; Jeffrey A Kant; Lisa A Cosentino; Leslie A Meyn; Sharon L Hillier Journal: Sex Transm Dis Date: 2006-12 Impact factor: 2.830
Authors: Nichole R Klatt; Ryan Cheu; Kenzie Birse; Alexander S Zevin; Michelle Perner; Laura Noël-Romas; Anneke Grobler; Garrett Westmacott; Irene Y Xie; Jennifer Butler; Leila Mansoor; Lyle R McKinnon; Jo-Ann S Passmore; Quarraisha Abdool Karim; Salim S Abdool Karim; Adam D Burgener Journal: Science Date: 2017-06-02 Impact factor: 47.728
Authors: Rebecca M Brotman; Mark A Klebanoff; Tonja R Nansel; Kai F Yu; William W Andrews; Jun Zhang; Jane R Schwebke Journal: J Infect Dis Date: 2010-11-10 Impact factor: 5.226
Authors: J Gregory Caporaso; Christian L Lauber; William A Walters; Donna Berg-Lyons; James Huntley; Noah Fierer; Sarah M Owens; Jason Betley; Louise Fraser; Markus Bauer; Niall Gormley; Jack A Gilbert; Geoff Smith; Rob Knight Journal: ISME J Date: 2012-03-08 Impact factor: 10.302
Authors: Jocelyn M Wessels; Julie Lajoie; Danielle Vitali; Kenneth Omollo; Joshua Kimani; Julius Oyugi; Juliana Cheruiyot; Makubo Kimani; John N Mungai; Maureen Akolo; Jennifer C Stearns; Michael G Surette; Keith R Fowke; Charu Kaushic Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240